RESAPHENE SUISSE AG
RESAPHENE SUISSE AG
Industry:
Fitness Gaming Health Care
Founded:
2015-02-12
Address:
Roggwil, Sankt Gallen, Switzerland
Country:
Switzerland
Website Url:
http://www.resaphene.ch
Total Employee:
1+
Status:
Active
Contact:
0041714500668
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Global Site Tag Sitelinks Search Box
Current Advisors List
Founder
Stock Details
Official Site Inspections
http://www.resaphene.ch Semrush global rank: 6.83 M Semrush visits lastest month: 756
- Host name: sites.framer.app
- IP address: 31.43.160.6
- Location: Makiyivka Ukraine
- Latitude: 48.0478
- Longitude: 37.9258
- Timezone: Europe/Kiev
- Postal: 20754
More informations about "Resaphene Suisse AG"
Home - tinniwell
Tinniwell® ist das weltweit erste Therapiesystem, dass es Ihnen ermöglicht, den Tinnitus-Ton selbst zu bestimmen und mittels individuell gefilterter Musik & Wärme zu behandeln. Ganz …See details»
Investor Relations - tinniwell
Jan 1, 2023 · E-Mail: [email protected]. German. English; Investor Relations. OTC Market. Resaphene Suisse AG. ISIN: CH0367465439 Valor: CH036746543. Aktueller Stand …See details»
Investor Relations - Tinniwell
Jan 1, 2023 · Resaphene Suisse AG ISIN: CH0367465439 Valor: CH036746543 Last Bid Price (23.11.2024)See details»
Resaphene Suisse AG Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Resaphene Suisse AG of Egnach, THURGAU. Get the latest business insights from Dun & Bradstreet.See details»
Resaphene Suisse AG - Crunchbase Company Profile & Funding
Health Care. Headquarters Regions Europe, Middle East, and Africa (EMEA) Founded Date Feb 12, 2015. Founders Anke Rauterkus. Operating Status Active. Legal Name Resaphene Suisse …See details»
Resaphene Suisse AG: FDA-Zulassungsprozess für Tinnitus …
Roggwil, den 13. Juli 2022 – Aufgrund der COVID-Pandemie wurden die Arbeiten für die FDA-Zulassung des tinniwell Anfang 2021 eingestellt. Diese wurde nun wieder aufgenommen und …See details»
Resaphene Suisse AG | LinkedIn - LinkedIn Schweiz
Die Resaphene Suisse AG ist führender Medizintechnik-Hersteller im Bereich Tinnitus-Therapie. Website. http://resaphene.ch. Branche. Arztpraxen. Größe. 2–10 Beschäftigte. Hauptsitz. …See details»
Resaphene Suisse AG: FDA Approval Process for Tinnitus Therapy ...
Jul 13, 2022 · Resaphene Suisse AG. Mrs. Anke Rauterkus (Chief Executive Officer) T. +41 714500668. [email protected]. Due to the COVID pandemic, work for the FDA …See details»
Resaphene Suisse AG: Breakthrough in Tinnitus Therapy
Aug 13, 2018 · Resaphene Suisse AG was founded in 2015 with the aim of developing a tinnitus therapy device with funds from the incubator of BS Health Group AG. After the prototype was …See details»
Overview - Tinniwell - resaphene.ch
A world first for tinnitus patients. OVER 50% TINNITUS RELIEF IN JUST 4 WEEKS. Scientifically proven and confirmed by patients: tinniwell can reduce Tinnitus symptoms by over 54.1% in …See details»
Revolutionary Tinniwell Therapy Offers Breakthrough in Tinnitus ...
May 6, 2024 · Resaphene Suisse AG unveils Tinniwell, a radical tinnitus treatment that combines heat and music therapy to provide personalized relief by targeting individual tinnitus frequencies.See details»
Resaphene Suisse AG: Tinnitus: 4 Phases Until Healing in the Tailor ...
May 18, 2020 · Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the …See details»
Resaphene Suisse AG: Tinnitus-Therapie tinniwell wird von …
Mar 17, 2019 · Ãœber die Resaphene Suisse AG: Die Resaphene Suisse AG (ISIN CH0367465439) wurde 2015 mit dem Ziel ein Tinnitus-Therapiegerät zu entwickeln mit Mitteln …See details»
Resaphene Suisse AG: FDA Approval Process for Tinnitus Therapy ...
Jul 13, 2022 · The management of Resaphene Suisse AG sees the time estimate and the widespread use of the therapy as unrealistic. Even if Neuralink's product were approved, we …See details»
Resaphene Suisse AG: Breakthrough in Tinnitus Therapy
Aug 13, 2018 · Since 2016 Resaphene Suisse AG (Vienna Stock Exchange: CH0367465439) sells the tinniwell. The device can be used by the patient in the home environment or even …See details»
Resaphene Suisse AG: Ethikkommission der Charité in
Jan 21, 2020 · Die Resaphene Suisse AG mit Sitz in Roggwil, Schweiz, ist ein Medizintechnik-Unternehmen, das 2015 gegründet wurde und seit 2016 unter dem Namen tinniwell ein …See details»
Resaphene Suisse AG Aktie (RESA) - MarketScreener
Mar 30, 2020 · Resaphene Suisse AG: Korrektur der Ad-hoc-Mitteilung vom 30.03.2020 Resaphene Suisse AG hat Zurückziehung der Einbeziehung im Vienna MTF bei der Wiener …See details»
Resaphene Suisse AG: FDA approval process for tinnitus therapy ...
Jul 13, 2022 · The management of Resaphene Suisse AG sees the time estimate and the widespread use of the therapy as unrealistic. Even if Neuralink's product were approved, we …See details»
Tinniwell | Oberhaching - Facebook
Tinniwell, Oberhaching. 601 likes. Resaphene stellt mit tinniwell eine Weltneuheit für Tinnitus-Betroffene vor: Ein Wellness-Gerät f .See details»
Resaphene Suisse AG: Breakthrough in Tinnitus — Tinniwell
Aug 14, 2018 · "By monitoring Resaphene in 250 patients from January 2019 - February 2020, 4 phases of therapy have now been identified. In phase 1, tinnitus becomes louder during or …See details»